Related Experiment Video
Updated: May 23, 2026
11:58
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Multimerization improves targeting of peptide radio-pharmaceuticals
Giuseppe Carlucci1, Hildo J K Ananias, Zilin Yu
1Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. g.carlucci@umcg.nl
Current Pharmaceutical Design
|April 6, 2012
Summary
Multimeric ligands, molecules with multiple parts, show enhanced binding properties. Tailoring these ligands improves their diagnostic and therapeutic potential by increasing selectivity and affinity.
Area of Science:
- Biochemistry and Molecular Biology
- Drug Discovery and Development
Background:
- Multimerization is a natural process conferring unique molecular properties.
- Multimeric ligands, composed of multiple units, can engage multiple receptors concurrently.
- This phenomenon is being explored for advanced diagnostic and therapeutic applications.
Purpose of the Study:
- To investigate the potential of molecular multimerization for enhancing ligand properties.
- To explore how structural modifications influence the binding characteristics of multimeric ligands.
- To assess the utility of multimeric ligands in diagnostic and therapeutic contexts.
Main Methods:
- Designing and synthesizing multimeric ligands with varied linker lengths, flexibility, and scaffolds.
- Investigating the impact of ligand-receptor recognition modulation on binding.
- Comparing the binding affinity and selectivity of multimeric ligands against their monomeric counterparts.
Main Results:
- Multimeric ligands exhibit superior binding affinity compared to monomeric versions.
- Modifications in linker properties and scaffold design significantly impact selectivity and affinity.
- The study demonstrates the feasibility of engineering multimeric ligands for specific receptor interactions.
Conclusions:
- Molecular multimerization is a powerful strategy for developing high-affinity and selective ligands.
- Optimizing multimeric ligand design offers significant advantages for diagnostic and therapeutic development.
- Engineered multimeric ligands represent a promising frontier in molecular medicine.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...